SG11201805162VA - Plasmid constructs for heterologous protein expression and methods of use - Google Patents
Plasmid constructs for heterologous protein expression and methods of useInfo
- Publication number
- SG11201805162VA SG11201805162VA SG11201805162VA SG11201805162VA SG11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- pct
- applicant
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562269702P | 2015-12-18 | 2015-12-18 | |
US201662375245P | 2016-08-15 | 2016-08-15 | |
PCT/US2016/067388 WO2017106795A1 (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201805162VA true SG11201805162VA (en) | 2018-07-30 |
Family
ID=59057754
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201805162VA SG11201805162VA (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
SG10201913163PA SG10201913163PA (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913163PA SG10201913163PA (en) | 2015-12-18 | 2016-12-16 | Plasmid constructs for heterologous protein expression and methods of use |
Country Status (10)
Country | Link |
---|---|
US (2) | US11713467B2 (ja) |
EP (1) | EP3390643B8 (ja) |
JP (2) | JP7079729B2 (ja) |
KR (1) | KR20190031424A (ja) |
CN (1) | CN109642240A (ja) |
AU (2) | AU2016369608B2 (ja) |
CA (1) | CA3009123A1 (ja) |
IL (2) | IL299646A (ja) |
SG (2) | SG11201805162VA (ja) |
WO (1) | WO2017106795A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2981049A1 (en) | 2015-03-26 | 2016-09-29 | Oncosec Medical Incorporated | Combination of an immunostimulatory cytokine and a checkpoint inhibitor for the treatment of malignancies |
AU2017268399B2 (en) | 2016-05-18 | 2023-01-12 | Modernatx, Inc. | mRNA combination therapy for the treatment of cancer |
US20190209652A1 (en) * | 2016-09-23 | 2019-07-11 | Oncosec Medical Incorporated | Modulating responses to checkpoint inhibitor therapy |
US20200123566A1 (en) * | 2017-06-13 | 2020-04-23 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
CN107164538B (zh) * | 2017-07-11 | 2021-03-02 | 复旦大学附属华山医院 | 一种检测calr基因突变的内参扩增引物组合物及其扩增体系 |
CA3093387A1 (en) * | 2018-03-08 | 2019-09-12 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
TW202039537A (zh) * | 2018-11-27 | 2020-11-01 | 美商昂科賽克醫療公司 | 用於治療癌症之質體建構體和使用方法 |
WO2020123602A1 (en) * | 2018-12-11 | 2020-06-18 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
BR112022002406A2 (pt) | 2019-08-12 | 2022-07-19 | Purinomia Biotech Inc | Métodos e composições para promover e potencializar respostas imunes mediadas por célula t através do alvejamento de adcc de células que expressam cd39 |
EP4031168A4 (en) | 2019-09-18 | 2023-10-11 | Intergalactic Therapeutics, Inc. | SYNTHETIC DNA VECTORS AND METHODS OF USE |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN112126644B (zh) * | 2020-11-25 | 2021-03-12 | 北京立康生命科技有限公司 | 一种非依赖帽结构下进行细胞外转录的mRNA、呈递细胞及应用 |
CA3207359A1 (en) | 2021-02-05 | 2022-08-11 | Cecile Chartier-Courtaud | Adjuvant therapy for cancer |
KR102393402B1 (ko) * | 2021-03-26 | 2022-05-04 | (주)와이디생명과학 | 세포 내 존재 단백질과 세포 외부로 분비되는 단백질을 동시 발현하는 이중발현벡터를 포함하는 암의 예방 또는 치료용 조성물 |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
CN116510022B (zh) * | 2022-11-23 | 2023-12-05 | 武汉滨会生物科技股份有限公司 | 一种用于抗肿瘤的组合物、重组质粒组合物及其应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
EP0803573A1 (en) * | 1996-04-25 | 1997-10-29 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronic expression construct with cytokines for multivalent vaccines |
US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
JP2002541855A (ja) | 1999-04-21 | 2002-12-10 | ジェンザイム・コーポレーション | 免疫調節分子コード核酸を含むアデノウイルスベクター |
AU6120600A (en) * | 1999-06-08 | 2000-12-28 | Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
DE60038622D1 (de) | 1999-10-20 | 2008-05-29 | Univ Johns Hopkins Med | Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure |
US6714816B1 (en) * | 2000-02-22 | 2004-03-30 | University Of South Florida | Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo |
AU3958101A (en) * | 2000-03-15 | 2001-09-24 | Univ Pohang | Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
DE10248141B4 (de) | 2002-10-11 | 2007-04-19 | Universitätsklinikum Hamburg-Eppendorf | Nukleinsäuren und deren Verwendung für die Gentherapie |
AU2004247071B2 (en) | 2003-05-30 | 2010-03-11 | University Of South Florida | Method for the treatment of malignancies |
US8802643B1 (en) | 2003-05-30 | 2014-08-12 | University Of South Florida | Method for the treatment of malignancies |
DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
WO2008046251A1 (fr) | 2006-10-19 | 2008-04-24 | Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. | Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées |
US9273300B2 (en) | 2007-02-07 | 2016-03-01 | Strike Bio, Inc | Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy |
KR100911624B1 (ko) | 2007-05-14 | 2009-08-12 | 연세대학교 산학협력단 | Il-12 및 il-23의 효율적인 공동발현 방법 |
JP2010531878A (ja) | 2007-06-27 | 2010-09-30 | マリン ポリマー テクノロジーズ,インコーポレーテッド | IL‐15とIL‐15Rαとの複合体及びその使用 |
WO2010042189A2 (en) | 2008-10-08 | 2010-04-15 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
MX362866B (es) | 2012-05-25 | 2019-02-20 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn. |
JP2017518764A (ja) | 2014-04-25 | 2017-07-13 | ストライク バイオ インコーポレイテッド | 癌の処置のための多標的指向RNAi |
CA2981474A1 (en) | 2015-03-31 | 2016-10-06 | Oncosec Medical Incorporated | Systems and methods for improved tissue-sensing based electroporation |
CN109561691A (zh) | 2016-06-07 | 2019-04-02 | 太平洋心肺血研究所 | 用于治疗癌症的组合物和方法 |
US20200123566A1 (en) | 2017-06-13 | 2020-04-23 | Oncosec Medical Incorporated | Multigene construct for immune-modulatory protein expression and methods of use |
-
2016
- 2016-12-16 US US16/062,983 patent/US11713467B2/en active Active
- 2016-12-16 JP JP2018532285A patent/JP7079729B2/ja active Active
- 2016-12-16 SG SG11201805162VA patent/SG11201805162VA/en unknown
- 2016-12-16 KR KR1020187020538A patent/KR20190031424A/ko not_active Application Discontinuation
- 2016-12-16 SG SG10201913163PA patent/SG10201913163PA/en unknown
- 2016-12-16 AU AU2016369608A patent/AU2016369608B2/en active Active
- 2016-12-16 CN CN201680081690.5A patent/CN109642240A/zh active Pending
- 2016-12-16 WO PCT/US2016/067388 patent/WO2017106795A1/en active Application Filing
- 2016-12-16 CA CA3009123A patent/CA3009123A1/en active Pending
- 2016-12-16 EP EP16876875.2A patent/EP3390643B8/en active Active
- 2016-12-16 IL IL299646A patent/IL299646A/en unknown
-
2018
- 2018-06-14 IL IL260039A patent/IL260039B2/en unknown
-
2020
- 2020-09-25 US US17/032,034 patent/US20210062218A1/en active Pending
-
2022
- 2022-05-23 JP JP2022083896A patent/JP2022116129A/ja active Pending
-
2023
- 2023-05-02 AU AU2023202722A patent/AU2023202722A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2017106795A1 (en) | 2017-06-22 |
IL260039B2 (en) | 2023-06-01 |
EP3390643B1 (en) | 2023-06-28 |
KR20190031424A (ko) | 2019-03-26 |
AU2016369608B2 (en) | 2023-02-02 |
CN109642240A (zh) | 2019-04-16 |
AU2023202722A1 (en) | 2023-05-18 |
IL260039A (en) | 2018-07-31 |
JP2022116129A (ja) | 2022-08-09 |
JP7079729B2 (ja) | 2022-06-02 |
EP3390643A4 (en) | 2019-08-28 |
EP3390643B8 (en) | 2023-08-02 |
JP2018537989A (ja) | 2018-12-27 |
IL299646A (en) | 2023-03-01 |
US20190153469A1 (en) | 2019-05-23 |
SG10201913163PA (en) | 2020-03-30 |
US20210062218A1 (en) | 2021-03-04 |
US11713467B2 (en) | 2023-08-01 |
EP3390643A1 (en) | 2018-10-24 |
CA3009123A1 (en) | 2017-06-22 |
AU2016369608A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201809144XA (en) | Materials and methods for treatment of hemoglobinopathies | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807366WA (en) | System and method for generating custom shoe insole | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
SG11201806002SA (en) | Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
SG11201810627UA (en) | Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases | |
SG11201903167QA (en) | Compounds and methods for reducing atxn3 expression | |
SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
SG11201808762XA (en) | Diagnostic methods for patient specific therapeutic decision making in cancer care |